Hormonal and Nutritional Effects on Cardiovascular Risk Markers in Young Women
Open Access
- 1 August 2007
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (8) , 3089-3094
Abstract
Context: Cardiovascular (CV) risk markers, including high-sensitivity C-reactive protein (hsCRP), are increasingly important in predicting cardiac events. A favorable CV risk profile might be expected in anorexia nervosa (AN) due to low body weight and dietary fat intake. However, women with AN have decreased IGF-I levels reflecting decreased GH action, and IGF-I deficiency is associated with elevated hsCRP. Moreover, oral estrogens, known to increase hsCRP in other populations, are commonly prescribed in AN. To date, hsCRP levels and their physiological determinants have not been reported in women with AN. Objective: We examined the relationship between CV risk markers, undernutrition, IGF-I, and oral estrogens, specifically hypothesizing that in the setting of undernutrition, AN would be associated with low hsCRP despite low IGF-I levels and that those women taking oral contraceptive pills (OCPs) would have higher hsCRP and lower IGF-I levels. Design and Setting: We conducted a cross-sectional study at a clinical research center. Study Participants: Subjects included 181 women: 140 women with AN [85 not receiving OCPs (AN-E) and 55 receiving OCPs (AN+E)] and 41 healthy controls [28 not receiving OCPs (HC-E) and 13 receiving OCPs (HC+E)]. Main Outcome Measures: We assessed hsCRP, IL-6, IGF-I, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). Results: Despite low weight, more than 20% of AN+E had high-risk hsCRP levels. AN+E had higher hsCRP than AN-E. AN-E had lower mean hsCRP levels than healthy controls (HC+E and HC-E). IL-6 levels were higher in AN+E with elevated hsCRP (>3 mg/liter) than in AN+E with normal hsCRP levels. IGF-I was inversely associated with hsCRP in healthy women, suggesting a protective effect of GH on CV risk. However, this was not seen in AN. Few patients in any group had high-risk LDL or HDL levels. Conclusions: Although hsCRP levels are lower in AN than healthy controls, OCP use puts such women at a greater than 20% chance of having hsCRP in the high-CV-risk (>3 mg/liter) category. The elevated mean IL-6 in women with AN and high-risk hsCRP levels suggests that increased systemic inflammation may underlie the hsCRP elevation in these patients. Although OCP use in AN was associated with slightly lower mean LDL and higher mean HDL, means were within the normal range, and few patients in any group had high-risk LDL or HDL levels. IGF-I levels appear to be important determinants of hsCRP in healthy young women. In contrast, IGF-I does not appear to mediate hsCRP levels in AN.Keywords
This publication has 60 references indexed in Scilit:
- Long-term mortality in anorexia nervosa: a report after an 8-year follow-up and a review of the most recent literatureEuropean Journal of Clinical Nutrition, 2006
- Etiology of hypercholesterolemia in patients with anorexia nervosaInternational Journal of Eating Disorders, 2006
- Hormone therapy, C-reactive protein, and progression of atherosclerosis: Data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trialAmerican Heart Journal, 2005
- Distribution and determinants of serum high‐sensitive C‐reactive protein in a population of young adults. The Cardiovascular Risk in Young Finns StudyJournal of Internal Medicine, 2005
- Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adultsInternational Journal of Obesity, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Effects of oestrogen replacement therapy on serum C-reactive protein levels in hysterectomised womenAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Effect of weight restoration on the dyslipoproteinemia of anorexia nervosaJournal of Adolescent Health, 1990